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Objective: Bacterial endocarditis is a frequent infectious cardiac disease, especially in patients with congenital or
acquired heart defects. It is characterized by bacterial colonization of the heart valves and the appearance of
vegetations consisting of fibrin, blood cells, and bacteria. The glycoprotein Deleted in Malignant Brain Tumors
1 is a scavenger receptor cysteine-rich protein with functions in innate immunity and epithelial differentiation.
Because of the aggregating capacity of Deleted in Malignant Brain Tumors 1, we hypothesized that an up-
regulation in bacterial endocarditis may be linked to the development of vegetations.
Methods: Heart tissue of 19 patients with bacterial endocarditis and 10 controls without bacterial endocarditis
was analyzed by immunohistochemistry. The effect of human recombinant Deleted in Malignant Brain Tumors
1 on erythrocyte aggregation was measured using an automated red blood cell aggregometer MA1. Binding of
human recombinant Deleted in Malignant Brain Tumors 1 to erythrocyte membranes, platelets, fibrin, and fibrin-
ogen was analyzed by Western blotting and enzyme-linked immunosorbent assay.
Results: Deleted in Malignant Brain Tumors 1 expression was up-regulated in affected heart valves with bacterial
endocarditis and limited to the colonizing bacteria on the heart valves and granulocyte-depleted fibrin/fibrinogen
formations, and around localized atheromatosis. Patients with aggressive bacteria showed higher DMBT1 levels
than patients with less aggressive bacteria. Human recombinant Deleted in Malignant Brain Tumors 1 aggregates
erythrocytes and binds to erythrocyte membranes, platelets, and fibrin/fibrinogen.
Conclusion: Deleted in Malignant Brain Tumors 1 up-regulation at sites of bacterial endocarditis, its association
with platelets and fibrin/fibrinogen, and its ability to aggregate erythrocytes through binding to their membranes
indicate a potential role in the development of vegetations and thrombosis.E
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SBacterial endocarditis includes infection of the heart valves
caused by intravascular bacteria, such as Staphylococcus
aureus, Staphylococcus epidermidis, and Streptococcus
sanguis, and is often accompanied by fibrin formation on en-
docardial tissue.1,2 Whereas bacterial endocarditis caused by
S aureus infection often leads to an acute and massive destruc-
tion of either previously intact heart valves or heart valves with
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and viridans streptococci such as S sanguis commonly induce
bacterial endocarditis in patients with already damaged
heart valves or with prosthetic cardiac devices in a more pro-
longed subacute clinical course.1-4 The formation of vegeta-
tions at the site of infection is a central process in the early
pathogenesis of bacterial endocarditis. Simplified, these veg-
etations mainly consist of fibrin, platelets, and the infecting
bacteria.1 Patients with bacterial endocarditis can have embo-
lism of part of the vegetations, leading to infectious insults in
different other organs. Another common and life-threatening
complication is sepsis. Fibrin thrombi have been observed in
the microvasculature of organs in patients with bacterial sep-
sis and concomitant multisystem organ failure, because sepsis
alters the procoagulant–anticoagulant balance with a decrease
in anticoagulant factors and an increase in procoagulant fac-
tors. Cytokines activate endothelial cells to up-regulate adhe-
sion receptors, which culminates in additional binding of
neutrophils, monocytes, macrophages, and platelets to the en-
dothelial cells enhancing the pathophysiologic condition.5
Deleted in Malignant Brain Tumors 1 (DMBT1), also
known as glycoprotein-340 or salivary agglutinin, is a se-
creted protein that belongs to the scavenger receptor cyste-
ine-rich group B protein family.6 DMBT1 has been
proposed to play a role in epithelial differentiation and
innate pathogen defense by acting as a pattern recognitionardiovascular Surgery c Volume 138, Number 3 725
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SAbbreviations and Acronyms
ACD ¼ acidic citrate dextrose
DMBT1 ¼ Deleted in Malignant Brain Tumors 1
hr ¼ human recombinant
HRP ¼ horseradish peroxidase
Ig ¼ immunoglobulin
PBS ¼ phosphate-buffered saline
molecule.7-10 Secreted and membrane-linked pattern recog-
nition molecules share the property to interact with a broad
range of pathogens through recognition of repeated molecu-
lar patterns commonly located on the pathogen surface. Ac-
cordingly, DMBT1 is most prominently expressed at sites
with frequent pathogen contacts, such as the respiratory
and gastrointestinal epithelium.6,7,9
DMBT1 interacts with surfactant proteins A and D,7,11,12
as well as with secretory immunoglobulin (Ig)A,13-15 acti-
vates the complement system, and may stimulate alveolar
macrophages.11,16 Furthermore, DMBT1 is up-regulated
during infections in infants and adults.17,18 In particular,
DMBT1 has been demonstrated to bind and aggregate a broad
range of bacteria, including Staphylococci and Streptococci,
which includes recognition of poly-phosphorylated surface
patterns (ie, lipopolysaccharide and lipoteichoic acid).19-22
To this end, in vitro studies suggest that DMBT1 interaction
with pathogens is sufficient to efficiently suppress viral and
bacterial infection.23-25 However, as recently reviewed, its
ability to bind and aggregate pathogens and other endoge-
nous interaction partners may also exert disease-promoting
effects in some scenarios.26 In the present study, we analyzed
DMBT1 expression in situ in bacterial endocarditis and its in-
teraction with platelets, erythrocytes, and fibrin/fibrinogen,
which represent the main constituents of endocarditis-associ-
ated vegetations and thrombi.
MATERIALS AND METHODS
Antibodies Used for Immunohistochemistry, Western
Blotting, Immunoblotting, and Enzyme-Linked
Immunosorbent Assay
For immunohistochemistry, we used the polyclonal anti-serum (anti-
DMBT1p84) generated against the recombinant DMBT1 in rabbit. Its spec-
ificity was confirmed by a comparison of immunohistochemical sections
with RNA in situ hybridization (data not shown). Western blots and
enzyme-linked immunosorbent assays were performed with the DMBT1-
specific monoclonal antibody Hyb213-06 (Antibodyshop, Gentofte,
Denmark) generated against DMBT1GP340, which was isolated from bron-
choalveolar lavage by Holmskov and coworkers.12 The specificity of this
antibody was confirmed by Western blotting.27
Immunohistochemical Analysis
We studied the cardiac tissue of 19 adults with bacterial endocarditis and
10 adults without endocarditis as controls (Table 1). The paraffin-embedded
sections were examined in cooperation with the Institute of Pathology,
University of Heidelberg, Germany. Tissue displaying no signal was scored726 The Journal of Thoracic and Cardiovascular Sur0. DMBT1-positive tissue was scored semiquantitatively from 1 (weak
staining) to 3 (highly intensive staining). The study was approved by the re-
sponsible ethics committee.
An automated Ventana Discovery stainer (Ventana Medical Systems,
Tucson, Ariz) was used for immunohistochemical studies with anti-
DMBT1p84. The anti-DMBT1p84 antibody was diluted 1:100 in Discovery
Ab Diluent, and sections were incubated for 40 minutes, followed by an
incubation for 30 minutes with mouse anti-rabbit IgG-AP (Santa Cruz Bio-
technology, Heidelberg, Germany) diluted 1:500. Peroxidase activity was
detected with 3-amino-9-ethylcarbazole as substrate (Sigma Chemicals, St
Louis, Mo). Negative control sections were stained with equal amounts of
normal rabbit IgG (Santa Cruz Biotechnology) to rule out unspecific binding.
Production and Purification of Human Recombinant
Deleted in Malignant Brain Tumors 1
Human recombinant (hr)DMBT1 was produced and purified as de-
scribed elsewhere.28 A concentration of 10 mg/mL hrDMBT1 corresponds
to approximately 40 nmol/L.
Erythrocyte Aggregation
Venous blood was collected from 8 healthy male volunteers of hospital
staff after informed consent. Blood samples were anticoagulated with
EDTA and lithium heparin to study the influence of calcium ions. Analysis
of the effects of calcium in EDTA-treated blood was not possible, because
EDTA completely binds calcium ions. EDTA was also added to lithium
heparinized blood to complex the calcium ions.
hrDMBT1 was added to the blood samples at final concentrations of 16
to 48 nmol/L. Because hrDMBT1 was dissolved in phosphate-buffered
saline (PBS), we used blood samples with equivalent volumes of PBS as
controls. The hematocrit was adjusted to 40% by adding plasma of the
same person to the blood sample. Erythrocyte aggregation was measured
using an automated red blood cell aggregometer MA1 (Myrenne GmbH,
Roetgen, Germany). After shearing at 600/s to disperse preexisting aggre-
gates, the erythrocyte aggregation of 20 mL blood sample at stasis (M)
was analyzed by integrating light transmission through the sample. The
experiments were performed at room temperature within 4 hours.
Incubation of Erythrocyte Membranes With Human
Recombinant Deleted in Malignant Brain Tumors 1
and Western Blotting
Lithium heparin blood (7.5 mL) was washed with 0.9% sodium chlo-
ride followed by centrifugation at 3000 rpm for 10 minutes and removal
of the supernatant. This washing procedure was performed 3 times. After
incubation of the erythrocytes with lysis buffer (4.15 g NH4Cl, 0.5 g
KHCO3, 0.02 g EDTA (Merck, Darmstadt, Germany) in 500 mL aqua;
pH 7.37), the lysed cells were centrifuged at 30,000g for 10 minutes and
the supernatant was removed. This erythrocyte lysis was performed 3
times. The pellets containing the erythrocyte membranes were incubated
with hrDMBT1 (solved in PBS; final concentration 200 nmol/L) or PBS
for 30 minutes, followed by washing with PBS. Then the pellets were
solved in 60 mL PBS as samples for Western blotting. The samples were
separated under nonreducing conditions on 7.5% polyacrylamide gels
(Tris-HCl; Bio-Rad Laboratories, Munich, Germany) followed by transfer
onto a nitrocellulose membrane. The membrane was blocked with 10%
(w/v) milk powder in PBS. For detection of DMBT1, we used the mono-
clonal antibody Hyb213-06 (1:1500–2000; AntibodyShop). A normal
mouse IgG antibody (Santa Cruz Biotechnology) in the same concentration
served as the control. As secondary antibody, a sheep anti-mouse IgG-
horseradish peroxidase (HRP) conjugate (1:1000; Chemicon, Temecula,
Calif) was used. The membranes were developed with an enhanced chem-
iluminescence kit (ECL Western Blotting Detection, Amersham, GE Health-
care, Braunschweig, Germany) according to the protocols provided by the
supplier.gery c September 2009
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STABLE 1. Clinical parameters and staining scores of controls and
cases
No. Age (y) Sex Heart tissue Score Bacteria
1 36 M Aortic valve 0.5 Control
2 78 F Aortic valve 0 Control
3 61 M Mitral valve 0.5 Control
4 72 F Aortic valve 1 Control
5 79 F Mitral valve 0.5 Control
6 62 M Aortic valve 1 Control
7 72 F Aortic valve 0 Control
8 83 M Aortic valve 0.5 Control
9 73 M Aortic valve 0.5 Control
10 54 M Aortic valve 0.5 Control
11 48 M Tricuspid valve
(ulcerous-polypous)
3 Staphylococcus
aureus
Mitral valve
(ulcerous-polypous)
12 72 M Mitral valve
(ulcerous-polypous)
2 S aureus
13 72 M Mitral valve
(ulcerous-polypous)
2.5 S aureus
14 78 M Aortic valve
(in part ulcerous)
3 S aureus,
Streptococcus
pneumoniae
15 75 M Mitral valve
(ulcerous-polypous)
2 MRSA
16 60 M Aortic valve
(ulcerous-polypous)
0.5 MRSA
17 58 M Aortic valve
(ulcerous-polypous)
3 MRSA
18 57 F Mitral valve
(ulcerous-polypous)
3 Escherichia coli
19 35 M Aortic valve (ulcerous) 1.5 Enterococcus
faecalisPulmonal valve
20 71 M Mitral valve
(ulcerous-polypous)
1.5 E faecalis
Aortic valve
(ulcerous-polypous)
21 47 M Aortic valve
(ulcerous-polypous)
1.5 E faecalis
22 36 M Aortic valve
(ulcerous-polypous)
1.5 S epidermidis
Mitral valve
(ulcerous-polypous)
23 36 M Aortic valve
(ulcerous-polypous)
1.5 S viridans
24 39 M Aortic valve
(ulcerous-polypous)
1.5 S viridans
25 52 M Aortic valve
(ulcerous-polypous)
0 S bovis
26 69 F Aortic valve 2 S lugdunensis
Tricuspid valve
27 32 F Mitral valve
(ulcerous-polypous)
1.5 Streptococcus
spp
28 45 M Mitral valve
(ulcerous-polypous)
1 Streptococcus
sppThe Journal of Thoracic andIncubation of Platelets With Human Recombinant
Deleted in Malignant Brain Tumors 1 and Western
Blotting
Five milliliters of acidic citrate dextrose (ACD: 85 mmol/L sodium cit-
rate, 65 mmol/L citric acid, 125 mmol/L dextrose) were added to 45 mL of
venous blood of a healthy volunteer followed by centrifugation at 800 rpm
for 20 minutes without brake. After gently mixing the platelet-rich plasma
with ACD (1 mL ACD per 5 mL platelet-rich plasma), centrifugation at
2100 rpm for 7 minutes with brake was performed. The supernatant was
then discarded, and the platelets were resuspended in washing buffer (Hepes
tyrode, consisting of 136 mmol/L sodium chloride, 2.68 mmol/L potassium
chloride, 0.98 mmol/L magnesium chloride, 3.26 mmol/L NaH2PO4, 3.78
mmol/L Hepes, 5.5 mmol/L glucose and adjusted to pH 7.35, and ACD)
followed by centrifugation at 2100 rpm for 4 minutes with brake. After re-
moval of the supernatant, the platelets were resuspended in PBS and
washed 3 times with PBS. Activation of platelets with 0.2 U/mL thrombin
(Haemochrom Diagnostica, Essen, Germany) was performed at 37C for 10
to 15 minutes in the presence of H-Gly-Pro-Arg-Pro-NH2 (5 mmol/L;
Sigma-Aldrich, Hamburg, Germany) to prevent platelet aggregation. After
3 washes with PBS, the platelets were incubated with a 200 nmol/L solution
of hrDMBT1 (hrDMBT1 was solved in PBS) or PBS alone for 60 minutes at
room temperature. Then the pellets were washed 3 times with PBS followed
by resuspension in PBS as samples for Western blotting (sodium dodecyl-
sulfate polyacrylamide gel electrophoresis, 7% acrylamide). Immunoblot-
ting was carried out as described above using the monoclonal antibody
Hyb213-06 (1:2500; AntibodyShop) for DMBT1 detection. In this immu-
noblot we used a goat anti-mouse IgG–HRP conjugate (1:20,000; Calbio-
chem, Gibbstown, NJ) as a secondary antibody. For comparison of the
loaded platelets in each line, we simultaneously used a goat antibody against
platelet/endothelial cell adhesion molecule (PECAM1) (1:1000; Santa Cruz
Biotechnology) and an anti-goat–IgG–HRP conjugate (1:20,000; Calbio-
chem) as secondary antibody.
Binding of Human Recombinant Deleted in
Malignant Brain Tumors 1 to Fibrin/Fibrinogen
Enzyme-linked immunosorbent assay microtiter plates (Greiner Bio-
One, Frickenhausen, Germany) were coated with fibrinogen (>70% clotta-
ble; Sigma-Aldrich) in serial 1:2 dilutions in carbonate buffer for 2 hours at
room temperature. Fibrin coating was performed similar to the description
by Sahni and Francis.29 Briefly, the wells were coated using 30 mg/mL fi-
brinogen (>70% clottable; Sigma-Aldrich) in PBS to which 1 U/mL throm-
bin (Haemochrom Diagnostica, Essen, Germany) was added. After mixing,
the solution was rapidly distributed to the consecutive wells in dilution steps
of 1:2 in carbonate buffer followed by aspiration after 45 seconds and before
polymerization. At 37C, this procedure leads to a thin fibrin coating of the
wells. After washing with PBS containing 2 mmol/L CaCl2, the plates
coated with fibrin/fibrinogen were incubated with a 0.4 nmol/L solution
of hrDMBT1 for 40 minutes at room temperature. After washing with
PBS/2 mmol/L CaCl2, a DMBT1-specific monoclonal mouse antibody
Hyb213-06 (1:5000; Antibodyshop) was added. Subsequently, the wells
were incubated with an HRP-conjugated anti-mouse antibody (1:10,000;
Calbiochem). The bound enzyme was detected by adding tetramethyl
benzidine-substrate solution (125 mg/mL 3,30,5,50-tetramethyl benzidine
TABLE 1. Continued
No. Age (y) Sex Heart tissue Score Bacteria
29 38 M Aortic valve
(ulcerous-polypous)
2 None (after long
therapy with
antibiotics)Tricuspid valve
(in part necrotizing)
MRSA, Methicillin-resistant Staphylococcus aureus. Bacteria were detected in blood
culture and/or in culture of an intraoperative smear of the concerned valves.Cardiovascular Surgery c Volume 138, Number 3 727
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SFIGURE 1. Immunohistochemical analysis of DMBT1 in heart tissues of patients without and with bacterial endocarditis. Binding sites for anti-DMBT1p84
are shown as brown staining. A–D, Heart tissue without endocarditis of 1 case with staining score 0 (A, B, no. 7 in Table 1) and 1 case with staining score 1 (C,
D, no. 6 in Table 1). E–H, Exemplary heart tissues of patients with endocarditis and less aggressive bacteria, with 1 case having a staining score of 0 (E, F, no.
25 in Table 1) and 1 case having a staining score of 1.5 (G, H, no. 24 in Table 1). I–L, Exemplary cardiac tissue of patients with endocarditis and aggressive
bacteria. Both cases (I, J, no. 11 in Table 1 and K, L, no. 18 in Table 1) show a staining score of 3. I, J, Bacteria (thick arrows) and neutrophils (fine arrows)
stain purple; DMBT1 is associated with bacteria and neutrophils. M, N (no. 14 in Table 1), Strong signals can be observed around localized atheromatosis. O,
P (no. 14 in Table 1), Positive DMBT1 signals are found in granulocyte-depleted fibrin/fibrinogen (lower part), whereas granulocyte-rich fibrin/fibrinogen
(upper part) remains negative. HE, Hematoxylin-eosin; DMBT1, deleted in malignant brain tumors 1.[Fluka, Sigma-Aldrich, Buchs SG, Switzerland] in 0.1 mol/L citrate buffer
pH 4.5 with 0.05% [v/v] H2O2). After incubation for 20 minutes in the dark,
the reaction was stopped by addition of 2 mol/L HCl. The intensity of the
dye reaction was measured at 450 nm in an enzyme-linked immunosorbent
assay reader (Victor2, Wallac, Turku, Finland). The analyses were done in
triplets. As control, wells without hrDMBT1 incubation and wells with only
carbonate buffer instead of fibrin/fibrinogen with and without hrDMBT1 in-
cubation were used. The extinction values obtained from the controls were
subtracted from the extinction values of the respective wells with DMBT1
incubation to normalize against nonspecific signals.
Statistics
All statistical calculations were performed with SAS software, release
9.1.3 (SAS Institute Inc, Cary, NC). Statistical analyzes for comparing the
scores of DMBT1 expression in cardiac tissue were performed with the
Mann–Whitney U test.728 The Journal of Thoracic and Cardiovascular SuA special model was used for analysis of the erythrocyte aggregation
data. Because the observations were correlated, data were analyzed by mul-
tilevel modeling using the SAS procedure PROC MIXED (SAS Institute
Inc). Patients’ identification was assumed as a random effect, whereas
hrDMBT1 concentration and anticoagulation method were considered
as fixed effects. Test results with P values less than .05 were regarded as
statistically significant.
RESULTS
Deleted in Malignant Brain Tumors 1 Is Prevalent at
Sites With Bacterial Endocarditis
DMBT1 was previously shown to interact with bacteria
in vitro, which also play a role for bacterial endocarditis,
such as S aureus and Streptococci.20 Moreover, an up-regu-
lation of DMBT1 expression was observed duringrgery c September 2009
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role of DMBT1 in cardiac infections, we first studied heart
tissues from 10 patients without bacterial endocarditis and
19 patients with bacterial endocarditis by immunohisto-
chemistry using DMBT1-specific antibodies. Eight of the
19 patients with endocarditis showed colonization with ag-
gressive bacteria (S aureus, Escherichia coli), and 8 of the
19 patients displayed colonization with less-aggressive bac-
teria (Enterococcus faecalis, S epidermidis, S viridans, S
bovis, S lugdunensis). This classification is provisional, be-
cause some bacteria may be reclassified in the future. There
are, for example, some reports that the coagulase-negative
bacterium S lugdunensis can also induce a very aggressive
course.31 In 2 patients with endocarditis, Streptococcus spe-
cies were found without the possibility of further character-
ization, and in 1 patient bacteria were not detectable after
long-term therapy with antibiotics (Table 1). In heart tissues
of adults without (Figure 1, A–D) and with (Figure 1, E–P)
bacterial endocarditis, signals could occasionally be de-
tected in parts of the connective tissue, some endothelia,
and in part of the myocytes, whereas no signals were
observed in the corresponding negative controls (data not
shown). Adult heart tissues with bacterial endocarditis
revealed strong signals associated with bacteria colonizing
the inflamed valves (Figure 1, I, J) and around localized
atheromatosis (Figure 1, M, N). Moreover, positive staining
was observed for granulocyte-depleted fibrin/fibrinogen
formations, whereas granulocyte-rich fibrin/fibrinogen for-
mations were negative (Figure 1, O, P). The staining scores
for the individual cases are depicted in Table 1. Statistical
analysis revealed a significant difference between the
DMBT1 score of patients with (median: 1.5, range: 0–3) and
without (median: 0.5, range: 0–1) endocarditis (P ¼ .0002).
Further, patients with less aggressive bacteria showed lower
DMBT1 levels (median: 1.5, range: 0–2) than patients with
FIGURE 2. Erythrocyte aggregation through hrDMBT1. Erythrocyte ag-
gregation was measured for each individual blood preparation (n ¼ 2–9
for the individual data points), and then the relative aggregation compared
with the sample without addition of DMBT1 was calculated for each indi-
vidual to account for interindividual differences. The diagram displays
mean values and standard errors of the mean. Conc, Concentration; Li, lith-
ium; hep, heparin; HrDMBT1, human recombinant deleted in malignant
brain tumors 1.The Journal of Thoracic and Caggressive bacteria (median: 2.75, range: 0.5–3) (P¼ .010).
The DMBT1 levels in patients with less aggressive bacteria
and patients with aggressive bacteria were significantly ele-
vated compared with the controls (P¼ .0048 and P¼ .0015,
respectively). Thus, in bacterial endocarditis DMBT1
was found in association with bacteria, as well as with athe-
romatosis and fibrin/fibrinogen formations, and its levels
correlated with the aggressiveness of the bacteria.
Deleted in Malignant Brain Tumors 1 Increases
Erythrocyte Aggregation In Vitro, Which Depends
on Plasma Components
DMBT1 interaction with bacteria commonly results in
bacterial aggregation, which consecutively may suppress
bacterial infection.20,32 However, it has been proposed that
interaction with and aggregation of host components could
result in disease-promoting effects of DMBT1.26 On the
basis of the prevalence of DMBT1 in fibrin/fibrinogen
formations, we next explored the effect of hrDMBT1 on
erythrocyte interaction and aggregation. To avoid interfering
effects, the experiments were performed using different anti-
coagulation agents (EDTA, lithium heparin, and lithium
heparinþEDTA). To normalize against interindividual dif-
ferences, we expressed the data as relative values compared
with the basal aggregation without hrDMBT1 addition.
Statistical analysis showed that upon addition of
hrDMBT1, the hrDMBT1 concentration (P ¼ .0003) as
well as the anticoagulation method (P<.0001) significantly
influenced the red blood cell aggregation. The data demon-
strated that hrDMBT1 promoted red blood cell aggregation,
which, however, was inhibited by the presence of EDTA
(Figure 2). A detectable increase of erythrocyte aggregation
in blood anticoagulated with lithium heparin started at
32 nmol/L (P< .0001) and was further augmented with
48 nmol/L hrDMBT1 (P< .0001).
Heat inactivation reduced, but did not completely abolish,
hrDMBT1-mediated erythrocyte aggregation (Figure 2). In ad-
dition, no aggregation took place when purified erythrocytes
were used regardless of whether native or heat-inactivated
hrDMBT1 was added. This suggests that DMBT1-mediated
erythrocyte aggregation may partly depend on the presence
of Ca ions and the 3-dimensional structure of the protein.
In particular, however, the data indicated that plasma compo-
nents might be necessary for DMBT1-mediated erythrocyte
aggregation.
Deleted in Malignant Brain Tumors 1 Displays
Plasma Component-Independent Binding to
Erythrocyte Membranes and Platelets In Vitro
To explore whether the putative plasma components are
required for aggregation of DMBT1-coated erythrocytes or
for binding of DMBT1 to the erythrocytes, we next tested
its ability to interact with the erythrocyte surface. HrDMBT1
readily interacted with membrane preparations ofardiovascular Surgery c Volume 138, Number 3 729
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SFIGURE 3. A, Analysis of DMBT1 binding to erythrocyte membranes.
Lane 1: purified hrDMBT1 solved in PBS (positive control); lane 2: erythro-
cyte membranes incubated with hrDMBT1; lane 3: erythrocyte membranes
without hrDMBT1 incubation (incubation with PBS only); lane 4: PBS wash-
ing solution extracted after the third washing step after hrDMBT1 incubation
of the erythrocyte membranes. Lane 2 demonstrates binding of hrDMBT1 to
erythrocyte membranes after hrDMBT1 incubation, whereas erythrocyte
membranes without hrDMBT1 incubation showed no bound DMBT1. B,
DMBT1 binding to platelets. Top: DMBT1 detection with the DMBT1-spe-
cific monoclonal antibody Hyb213-06. Bottom: detection of platelet/endo-
thelial cell adhesion molecule (PECAM1) with a platelet/endothelial cell
adhesion molecule–specific antibody as a control for equivalent loading amounts
of platelets.Lane1: purified hrDMBT1 solved in PBS serving as the positive con-
trol for DMBT1 detection; lane 2: platelets incubated with hrDMBT1; lane 3:
platelets without hrDMBT1incubation (incubationwith PBS); lane4: platelets
incubated with hrDMBT1 after activation by thrombin in the presence of
H-Gly-Pro-Arg-Pro-NH2 to prevent platelet aggregation; lane 5: platelets
without hrDMBT1 incubation (incubation with PBS) after activation by
thrombin in the presence of H-Gly-Pro-Arg-Pro-NH2 to prevent platelet aggre-
gation; lane 6: PBS washing solution extracted after the third washing step af-
ter hrDMBT1 incubation of the platelets (lane2); lane7: PBS washingsolution
extracted after the third washing step after hrDMBT1 incubation of the acti-
vated platelets (lane 4). DMBT1 attaches to both nonactivated (lane 2) and ac-
tivated platelets (lane4) with nomajor differences. C, hrDMBT1 interacts with
immobilized fibrinogen in a concentration-dependent manner.Control: exper-730 The Journal of Thoracic and Cardiovascular Surerythrocytes in the absence of plasma as demonstrated by
Western blotting (Figure 3, A).
We next tested binding to purified platelets, because these
are more relevant for the formation of vegetations during
bacterial endocarditis. In the absence of plasma components,
DMBT1 also readily bound to the surface of platelets with
no major differences between nonactivated and thrombin-acti-
vated platelets (Figure 3, B). Thus, we conclude that DMBT1
interaction with the surface of erythrocytes and platelets does
not depend on the presence of soluble plasma components,
whereas the aggregation of erythrocytes apparently does.
Deleted in Malignant Brain Tumors 1 Interacts with
Fibrin and Fibrinogen In Vitro
The initial immunohistochemical studies indicated strong
staining of fibrin/fibrinogen formations, raising the possibility
that fibrinogen might represent a plasma component that
causes aggregation of DMBT1-coated erythrocytes and/or
platelets. We therefore finally explored whether DMBT1
might interact with fibrinogen and/or fibrin. By using serially
diluted fibrinogen and fibrin immobilized on enzyme-linked
immunosorbent assay plates, we found that hrDMBT1
bound in a concentration-dependent manner to both fibrino-
gen and fibrin with a stronger binding activity for fibrinogen
(Figure 3, C, D).
DISCUSSION
DMBT1 is known to interact with and aggregate bacteria
such as Streptococci and Staphylococci.14,19-21 We thus
hypothesized a relationship to bacterial endocarditis. Initial
evidence has accumulated that DMBT1 may represent
a protein with ambivalent character, possibly exerting both
disease-preventing and promoting effects.26 For example,
its ability to aggregate bacteria may exert beneficial effects
in terms of suppression of infection and inflammation.19,32,33
On the other hand, DMBT1-mediated aggregation of choles-
terol may promote gallstone formation, and it has been pro-
posed that some pathogens may use DMBT1 for adhesion to
host structures (reviewed in Mollenhauer and colleagues26).
Subacute infective endocarditis may develop through in-
vasion of bacteria in a preexisting thrombus, whereas in
acute infective endocarditis the thrombus could be initiated
by the invading organism (ie, S aureus) or the valvular
trauma from intravenous catheters or pacing wires. S aureus
can invade the endothelial cells and increase the expression
of adhesion molecules and the procoagulant activity.34,35
iments, in which hrDMBT1 incubation was omitted (negative control). Error
bars are standard errors of the means. D, hrDMBT1 interacts with immobilized
fibrin in a concentration-dependent manner. Control: experiments, in which
hrDMBT1 incubation was omitted (negative control). Error bars are standard
errors of the mean. DMBT1, Deleted in malignant brain tumors 1.
:gery c September 2009
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lesions associated with bacterial endocarditis. Further, we
detected higher DMBT1 levels in patients with endocarditis
with aggressive bacteria in comparison with patients with
endocarditis with less aggressive bacteria. Moreover, our
data suggest that DMBT1 is able to interact with the eryth-
rocyte and platelet surfaces as well as with fibrin and
fibrinogen, which may play a role in DMBT1-mediated
erythrocyte and platelet aggregation.
Although the precise mode of interaction between
DMBT1 and fibrinogen/fibrin remains to be elucidated,
our data suggest a stronger binding to immobilized fibrino-
gen than to immobilized fibrin. Binding to fibrinogen
reached saturation, whereas the binding curve for fibrin still
seems to be in the linear range at the concentrations tested
(Figure 3, C, D). Both fibrinogen and fibrin harbor interac-
tion sites such as the RGD motif (fibrinogen) or the
b15–42 region (fibrin), which are important for mediating
molecular and cellular interactions.36 The fact that
DMBT1 can specifically be found in granulocyte-depleted
but not in granulocyte-rich fibrinogen/fibrin formations
could indicate that DMBT1 binds to or sterically hinders
access to these motifs in fibrinogen and fibrin.
On the basis of these data, one may assume that it is
beneficial to keep the DMBT1 levels in the bloodstream at
a minimum to avoid clogging of blood components. This
could be reflected by the patterns observed for endothelia
in the heart tissues analyzed within this study. Occasional
positivity of endothelial cells indicates low or no basal secre-
tion of DMBT1 in the bloodstream and inducibility in
response to yet to be defined stimuli. Similar observations
have been made for various other cell types, such as lung
and intestinal epithelial cells, of which the latter have been
shown to up-regulate DMBT1 in response to bacterial sur-
face structures, and tumor necrosis factor-a.17,18,32,33,37 In
particular, both the lung and the gastrointestinal tract like-
wise represent examples for tissues in which a limitation
of DMBT1 levels could be beneficial. In the respiratory tract,
DMBT1 is assumed to counteract infections, but on the other
hand, it may increase the surface tension of the surfactant to
a level, presumably interfering with proper ventilation when
exceeding certain thresholds.7,25,37 In the gastrointestinal
tract, DMBT1 may be anti-inflammatory and prevent bacte-
rial infection and/or access of the endogenous microflora to
the epithelial cells.32,33 On the other hand, however, mouse
Dmbt1 is the major sulfated glycoprotein in intestinal plugs
occurring in the Cftr knockout mouse.38
Accordingly, different mechanisms are conceivable by
which DMBT1 could be involved in bacterial endocarditis
and associated atheromatosis. Accumulation of DMBT1 at
the site of the lesion can be promoted by bacterial coloniza-
tion and/or its association with fibrinogen/fibrin, which in
turn could accelerate bacterial adhesion to the thrombus
and/or the deposition of platelets. Alternatively, DMBT1The Journal of Thoracic andcould promote the interaction between bacteria and fibrin
or platelets. Being covered by fibrin and platelets, bacteria
are shielded from immune cells and defense factors.39 It is
tempting to speculate that the binding of DMBT1 to fibrin-
ogen/fibrin, erythrocytes, and platelets might play a role in
other cardiovascular diseases such as atherosclerosis and
thrombosis, which has not been addressed to date. Immuno-
histochemical analyses analogous to the present study may
represent a starting point to test this hypothesis. Remarkably,
however, a similar role has been proposed for surfactant
protein-D, which is one of the DMBT1 interaction partners.
Surfactant protein-D knockout mice develop significantly
reduced atherosclerotic lesions compared with wild-type
mice, indicating a proatherogenic role for surfactant
protein-D.40
CONCLUSIONS
Our data demonstrate an enrichment of DMBT1 in le-
sions associated with bacterial endocarditis, in particular
vegetations, and simultaneously show that DMBT1 has
the capacity to aggregate erythrocytes in vitro. Further,
DMBT1 binds to erythrocyte and platelet surfaces and inter-
acts with immobilized fibrinogen and fibrin in a concentra-
tion-dependent manner. These data indicate a possible
role of DMBT1 in the formation of bacterial endocarditis-
associated atheromatosis.
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